PL2500036T3 - Inhibitory met do zwiększania skuteczności radioterapii - Google Patents

Inhibitory met do zwiększania skuteczności radioterapii

Info

Publication number
PL2500036T3
PL2500036T3 PL11158861T PL11158861T PL2500036T3 PL 2500036 T3 PL2500036 T3 PL 2500036T3 PL 11158861 T PL11158861 T PL 11158861T PL 11158861 T PL11158861 T PL 11158861T PL 2500036 T3 PL2500036 T3 PL 2500036T3
Authority
PL
Poland
Prior art keywords
met inhibitors
enhancing radiotherapy
radiotherapy efficacy
efficacy
enhancing
Prior art date
Application number
PL11158861T
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Carla Boccaccio
Fiorella Petronzelli
Santis Rita De
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Publication of PL2500036T3 publication Critical patent/PL2500036T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL11158861T 2011-03-18 2011-03-18 Inhibitory met do zwiększania skuteczności radioterapii PL2500036T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy

Publications (1)

Publication Number Publication Date
PL2500036T3 true PL2500036T3 (pl) 2014-10-31

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11158861T PL2500036T3 (pl) 2011-03-18 2011-03-18 Inhibitory met do zwiększania skuteczności radioterapii

Country Status (23)

Country Link
US (1) US20120237524A1 (pl)
EP (1) EP2500036B1 (pl)
JP (1) JP5671487B2 (pl)
KR (1) KR101540838B1 (pl)
CN (1) CN102688491A (pl)
AU (1) AU2012201303B2 (pl)
BR (1) BR102012006063B1 (pl)
CA (1) CA2769991C (pl)
CY (1) CY1115374T1 (pl)
DK (1) DK2500036T3 (pl)
EA (1) EA028590B1 (pl)
ES (1) ES2489475T3 (pl)
HK (1) HK1174539A1 (pl)
HR (1) HRP20140729T1 (pl)
IL (1) IL218293A (pl)
MX (1) MX2012003084A (pl)
PL (1) PL2500036T3 (pl)
PT (1) PT2500036E (pl)
RS (1) RS53468B (pl)
SG (1) SG184637A1 (pl)
SI (1) SI2500036T1 (pl)
SM (1) SMT201400106B (pl)
ZA (1) ZA201201992B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1592713A2 (en) * 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
RS53476B (en) * 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
KR101429297B1 (ko) * 2006-02-06 2014-08-12 메테레시스 트랜스레이셔날 리서치 에스.에이. 종양 치료를 위한 항-Met 단클론 항체, 이의 단편과벡터 및 상응하는 산물
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
SI2500036T1 (sl) 2014-09-30
BR102012006063A8 (pt) 2022-11-08
SMT201400106B (it) 2014-11-10
CY1115374T1 (el) 2017-01-04
HK1174539A1 (en) 2013-06-14
CA2769991C (en) 2018-05-15
AU2012201303A1 (en) 2012-10-04
BR102012006063B1 (pt) 2023-03-07
IL218293A (en) 2016-06-30
JP2012196206A (ja) 2012-10-18
EA201200329A3 (ru) 2013-01-30
EA028590B1 (ru) 2017-12-29
JP5671487B2 (ja) 2015-02-18
HRP20140729T1 (hr) 2014-08-29
EA201200329A2 (ru) 2012-09-28
AU2012201303B2 (en) 2013-11-07
EP2500036A1 (en) 2012-09-19
DK2500036T3 (da) 2014-08-04
CN102688491A (zh) 2012-09-26
SG184637A1 (en) 2012-10-30
BR102012006063A2 (pt) 2021-11-16
ES2489475T3 (es) 2014-09-02
MX2012003084A (es) 2012-09-17
IL218293A0 (en) 2012-07-31
EP2500036B1 (en) 2014-05-07
CA2769991A1 (en) 2012-09-18
ZA201201992B (en) 2015-05-27
US20120237524A1 (en) 2012-09-20
PT2500036E (pt) 2014-08-25
KR20120106582A (ko) 2012-09-26
RS53468B (en) 2014-12-31
KR101540838B1 (ko) 2015-08-06

Similar Documents

Publication Publication Date Title
HK1257823A1 (zh) 金屬酶抑制劑化合物
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2753334A4 (en) FAP-ACTIVATED PROASEASOME INHIBITORS FOR TREATING SOLID TUMORS
EP2776126A4 (en) DEFINITION OF EFFECTIVE DEFIBRILLATION
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
HK1200840A1 (en) Dpp-4 inhibitor dpp-4
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2694057A4 (en) LIPOXYGENASE INHIBITORS
HK1174539A1 (en) Met inhibitors for enhancing radiotherapy efficacy met
EP2768512A4 (en) ENZYME HAMMER FOR CANCER TREATMENT
ZA201306074B (en) Cathepsin c inhibitors
GB201120474D0 (en) Inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
IL225527A0 (en) Matrix metalloproteinase inhibitors
IL225528A0 (en) Matrix metalloproteinase inhibitors
IL225526A0 (en) Matrix metalloproteinase inhibitors
GB201104399D0 (en) Novel inhibitors